U.S. pharma big copyright scrapped two experimental weight loss products last year—a when-each day capsule, lotiglipron, because of elevated liver enzymes as well as a twice-day by day tablet, danuglipron, as a consequence of powerful Unintended effects—but CEO Albert Bourla has explained the company is set to “Participate in and gain” with